Johnson D H, Hainsworth J D, Hande K R, Greco F A
Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN.
Semin Oncol. 1992 Dec;19(6 Suppl 14):19-24.
Chronic administration of etoposide over multiple days has proved to be an effective schedule against a variety of neoplasms. The usual duration of etoposide administration is 3 to 5 days. However, recent studies have demonstrated this agent can be administered for up to 21 consecutive days with acceptable toxicity. Studies are currently under way to determine whether more protracted etoposide administration will prove to be more efficacious in the management of selected malignancies. Previous work at our institution has confirmed the activity of protracted administration of single-agent etoposide against small cell lung cancer and non-small cell lung cancer. More recently, we have combined either cisplatin or carboplatin with etoposide given orally for 21 consecutive days in phase II trials in patients with small cell lung cancer and non-small cell lung cancer. The results of these trials are reviewed.
连续多日给予依托泊苷已被证明是针对多种肿瘤的有效给药方案。依托泊苷的常规给药时长为3至5天。然而，近期研究表明，该药物连续给药长达21天，毒性仍在可接受范围内。目前正在进行研究，以确定更长时间给予依托泊苷在治疗某些恶性肿瘤方面是否会更有效。我们机构之前的研究已经证实，长期给予单药依托泊苷对小细胞肺癌和非小细胞肺癌有活性。最近，我们在小细胞肺癌和非小细胞肺癌患者的II期试验中，将顺铂或卡铂与依托泊苷联合，连续21天口服给药。本文对这些试验的结果进行了综述。
